Tradename: ALTUVIIIO
Proper Name: antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl
Indication: Indicated for use in adults and children with Hemophilia A (congenital Factor VIII deficiency) for: (1) Routine prophylaxis to reduce the frequency of bleeding episodes; (2) On-demand treatment and control of bleeding episodes; and (3) Perioperative management of bleeding.
Approval Date: 02/22/2023
Manufacturer: Bioverativ Therapeutics, Inc.
More: https://www.fda.gov/vaccines-blood-biologics/altuviiio